EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors

Maxime Chénard-Poirier iD, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01428-0 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Maxime Chénard-Poirier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre intégré de cancérologie du CHU de Québec - Université Laval, 2250 Blvd Henri-Bourassa, Quebec, QC, G1J 5B3, Canada. maxime.chenard-poirier.1@u…. Hauptthemen laut MEDLINE: Benzimidazoles, Antibodies, Monoclonal, Humanized, Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MEK inhibitors have immunomodulatory activity and potential for synergistic activity when combined with PD-1 inhibitors. We evaluated selumetinib (inhibitor of MEK1/2) plus pembrolizumab (anti‒PD-1 antibody) in patients with advanced/metastatic solid tumors. In this phase 1b study, adults with previously treated advanced/metastatic solid tumors received pembrolizumab 200 mg intravenously every 3 weeks plus selumetinib on days 1‒14 per 3-week cycle (2 weeks on/1 week off); selumetinib dosing began at 50 mg orally twice daily with escalation in 25 mg increments for ≤ 35 cycles. Primary endpoints were dose-limiting toxicities (DLTs), adverse events (AEs), and treatment discontinuations due to AEs. Thirty-two patients were enrolled. Dose escalation was completed up to selumetinib 125 mg twice daily. The target DLT rate of 30% was not reached at any dose level. In the selumetinib 100 mg group, 2/11 patients (18.2%) experienced DLTs (n = 1 grade 3 diarrhea, n = 1 grade 3 fatigue). In the selumetinib 125 mg group, 3/14 (21.4%) experienced DLTs (n = 1 grade 2 retinal detachment, n = 1 grade 3 retinopathy, n = 1 grade 3 stomatitis). Dose-related changes in pharmacokinetic exposures were observed for selumetinib and N -desmethyl selumetinib up to 100 mg (saturation at 125 mg). Two patients achieved partial responses (1 each with selumetinib 75 mg and 125 mg) for an objective response rate of 6%. The study was stopped early because of insufficient efficacy. Although the target DLT rate was not reached at any dose level and no new safety signals were identified, selumetinib plus pembrolizumab had limited antitumor activity in this population. Trial registration: ClinicalTrials.gov , NCT03833427.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesAntibodies, Monoclonal, HumanizedNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedAdultProtein Kinase InhibitorsMaximum Tolerated DoseDose-Response Relationship, DrugAged, 80 and over

Stichwörter der Autor:innen

Clinical trialMEKPembrolizumabSelumetinibSolid tumors

Substanzen

AZD 6244BenzimidazolesAntibodies, Monoclonal, HumanizedpembrolizumabProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Centre intégré de cancérologie du CHU de Québec - Université Laval, 2250 Blvd Henri-Bourassa, Quebec, QC, G1J 5B3, Canada. maxime.chenard-poirier.1@ulaval.ca.
  • Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, TX, USA.
  • City of Hope National Medical Center, Duarte, CA, USA.
  • Merck & Co., Inc., Rahway, NJ, USA.

ORCID-Profile: Maxime Chénard-Poirier

Zitieren

APA

Chénard-Poirier, M., Hansen, A. R., Gutierrez, M. E., Rasco, D., Xing, Y., Chen, L. C., Zhou, H., Webber, A. L., Freshwater, T., & Sharma, M. R. (2024). A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01428-0

Vancouver

Chénard-Poirier M, Hansen AR, Gutierrez ME, Rasco D, Xing Y, Chen LC, et al. A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01428-0

BibTeX
@article{ChnardPoirier2024,
  author = {Chénard-Poirier, Maxime and Hansen, Aaron R and Gutierrez, Martin E and Rasco, Drew and Xing, Yan and Chen, Lin-Chi and Zhou, Heng and Webber, Andrea L and Freshwater, Tomoko and Sharma, Manish R},
  title = {A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01428-0}
}
Kostenlos starten →